MAZE vs ACMR vs ICHR vs RARE vs MKSI vs JPM

For growth investors, Ultragenyx Pharmaceutical Inc.

(RARE) is the stronger pick with 20. 1% revenue growth year-over-year, versus -100. 0% for Maze Therapeutics, Inc. (MAZE). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Maze Therapeutics, Inc. (MAZE) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus MKS Inc. at 81. 4x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus ACM Research, Inc. 's 1. 33x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, ACM Research, Inc.

(ACMR) delivered a total return of +192. 4%, compared to -76. 3% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: ACMR returned +49. 2% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), JPMorgan Chase & Co.

(JPM) is the lower-risk stock at 0. 94β versus Ichor Holdings, Ltd. 's 3. 97β — meaning ICHR is approximately 321% more volatile than JPM relative to the S&P 500. On balance sheet safety, Maze Therapeutics, Inc. (MAZE) carries a lower debt/equity ratio of 7% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ultragenyx Pharmaceutical Inc.

(RARE) is pulling ahead at 20. 1% versus -100. 0% for Maze Therapeutics, Inc. (MAZE). On earnings-per-share growth, the picture is similar: MKS Inc. grew EPS 55. 5% year-over-year, compared to -40. 2% for Maze Therapeutics, Inc.. Over a 3-year CAGR, ACMR leads at 32. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -612. 7% for Maze Therapeutics, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -670. 3% for MAZE. At the gross margin level — before operating expenses — MAZE leads at 92. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus ACM Research, Inc. 's 1. 33x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 4x forward P/E versus 63. 0x for Ichor Holdings, Ltd. — 48. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MAZE: 163. 0% to $63. 25.

In this comparison, JPM (1.

9% yield), MKSI (0. 2% yield), ACMR (0. 1% yield) pay a dividend. MAZE, ICHR, RARE do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). ACM Research, Inc. (ACMR) carries a higher beta of 3. 46 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, ACMR: +49. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MAZE (Healthcare) and ACMR (Technology) and ICHR (Technology) and RARE (Healthcare) and MKSI (Technology) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MAZE is a small-cap quality compounder stock; ACMR is a small-cap high-growth stock; ICHR is a small-cap quality compounder stock; RARE is a small-cap high-growth stock; MKSI is a mid-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while MAZE, ACMR, ICHR, RARE, MKSI do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.